1. A system (1) for processing configuration data of a communication network, characterized in that it includes first calculation means (3) adapted to determine a network usage predictive state from first data representative of the usage of resources andor services within said network and second calculation means (4) adapted to determine a network evolution planning proposal from said usage predictive state and second data representative of plant (Ri, ERj) of said network and said first calculation means (3) are adapted to determine usage profiles of service level agreements (7) between the operator of the network and customers from said first data and from said service level agreements.
2. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine said network usage predictive state from complementary third data representative of user requirement prediction information.
3. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine a service level agreement usage profile (7) for each service level agreement.
4. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine a service level agreement usage predictive profile constituting said network usage predictive state from said service level agreement usage profiles (7).
5. A system according to claim 1, wherein the said first calculation means (3) are adapted to determine a service level agreement usage predictive profile constituting said network usage predictive state from said service level agreement usage profiles (7); and wherein said service level agreement usage predictive profile from said third data and said service level agreement usage profiles.
6. A system according to claim 1, characterized in that said first data is chosen in a group comprising the current usage of resources andor services of the network and at least a portion of the record of usage of the resources andor services of said network.
7. A system according to claim 5, characterized in that said first calculation means (3) are adapted to determine said service level agreement usage profiles (7) by means of a trend evolution analysis.
8. A system according to claim 1, characterized in that said third data is chosen in a group comprising the future types of service level agreements and the future evolution of service subscriptions.
9. A system according to claim 1, characterized in that said second calculation means (4) include traffic engineering means (12) adapted to determine an optimum configuration of the network from said second data describing the plant (Ri, ERj) of said network and a usage predictive state and predictive state validation means (11) adapted i) to supply said traffic engineering means (12) with said predictive state delivered by said first calculation means (3) and ii) on receiving an optimum configuration associated with said predictive state to determine whether said network can support said optimum configuration or not and then, if it cannot, to determine the network plant liable to be disturbed by the evolution of the network corresponding to said predictive state.
10. A system according to claim 9, characterized in that said second calculation means (4) include planning determination means (13) connected to a planning database (14) and adapted to determine said planning proposal from the designation of the disturbed plant and said planning data from said database.
11. A system according to claim 10, characterized in that said planning determination means (13) are adapted to deliver a planning proposal minimizing the costs of network evolution.
12. A system according to claim 10, characterized in that at least some of said planning data takes the form of planning rules.
13. A system according to claim 10, characterized in that said planning determination means (13) are adapted, before delivering said planning proposal, to supply said traffic engineering means (12) so that they determine a new optimum configuration corresponding to said network evolution planning proposal and said validation means (11) are adapted, on receiving a new optimum configuration associated with said planning proposal, to determine if said network, as defined by said planning proposal, can support said new optimum configuration or not and then, if it can, to send to said planning determination means (13) an authorization to deliver said planning proposal and, if it cannot, to determine the network plant liable to be disturbed by said planning proposal and to send to said planning determination means (13) the designation of said disturbed plant for them to determine a new planning proposal.
14. A system according to claim 1, characterized in that it includes a graphical user interface (5) adapted to enable the definition of said third data by an operator and the display of each planning proposal.
15. A system according to claim 13, characterized in that it includes a graphical user interface (5) adapted to enable the definition of said third data by an operator and the display of each planning proposal, wherein said graphic user interface (5) is adapted to enable an operator to monitor the validation of planning proposals.
16. A system (2) for managing a communication network, characterized in that it includes a processing system (1) according to claim 1.
17. A method of processing communication network configuration data, characterized in that it consists in determining i) a network usage predictive state from first data representative of the usage of resources andor services within said network and ii) a network evolution planning proposal from said usage predictive state and second data representative of plant (Ri, ERj) of said network, and in that usage profiles of service level agreements (7) between the operator of the network and customers are determined from said first data and said service level agreements.
18. A method according to claim 17, characterized in that said network usage predictive state is determined from complementary third data representative of user requirement prediction information.
19. Use of a method, a processing system (1), and a management system (2) according to claim 1 in networks chosen in a group comprising Internet (IP), MPLSGMPLS, ATM and Frame Relay networks.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound having the formula:
wherein,
Q is (CHR6)1-3;
R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkaryl, optionally substituted C1-4 alkheterocyclyl, or optionally substituted C2-9 heterocyclyl;
each of R2 and R3 is, independently, H, Hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A, or optionally substituted C1-4 alkheterocyclyl,
wherein r2 is an integer from 0 to 2, R2A is optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-4 alkaryl, optionally substituted C2-9 heterocyclyl, optionally substituted C1-4 alkheterocyclyl, optionally substituted C1-6 thioalkoxy, optionally substituted C1-4 thioalkaryl, optionally substituted aryloyl, optionally substituted C1-4 thioalkheterocyclyl, or optionally substituted amino;
each of R4 and R5 is independently H, Hal, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A;
wherein Y1 and Y2 are each H, or Y1 and Y2 together are \u2550O, or Y1 and Y2 are independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, or optionally substituted C1-4 alkheterocyclyl;
wherein only one of R2, R3, R4, and R5 is (CH2)r2NHC(NH)R2A or (CH2)24NHC(S)NH2A;
or a pharmaceutically acceptable salt or prodrug thereof.
2. The compound of claim 1,
wherein,
Q is (CHR6)1-3;
R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkaryl, optionally substituted C1-4 alkheterocyclyl, or optionally substituted C2-9 heterocyclyl;
each of R2 and R3 is, independently, H, Hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, or optionally substituted C1-4 alkheterocyclyl;
each of R4 and R5 is, independently, H, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A
wherein Y1 and Y2 are each H, or Y1 and Y2 together are \u2550O;
wherein one, but not both, of R4 and R5 is H;
or a pharmaceutically acceptable salt or prodrug thereof.
3. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is (CHR6)2.
4. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)2.
5. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is CHR6.
6. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is CHR6.
7. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is (CHR6)3.
8. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)3.
9. The compound of claims 1, wherein R4 or R5 has the formula:
wherein Z is R2A.
10. The compound of claim 9, wherein R2A has the formula:
each of X1, X2, X4, and X5 is independently selected from O, S, NR7, N, or CR8; X3 is selected from N or CR8;
R7 is H or optionally substituted C1-6 alkyl;
R8 is H, Hal, optionally substituted C1-6 alkyl, hydroxy, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 thioalkoxy,
wherein at least one of X1, X2, X4, and X5 is not CR8.
11. The compound of claim 10, wherein R2A has the formula:
each of X1 and X2 is independently selected from O, S, NH, N, or CH;
wherein at least one of X1 and X2 is not CH.
12. The compound of claims 1, wherein R2 or R3 has the formula:
wherein Z is R2A.
13. The compound of claim 12, wherein R2A has the formula:
each of X1, X2, X4, and X5 is independently selected from O, S, NR7, N, or CR8; X3 is selected from N or CR8;
R7 is H or optionally substituted C1-6 alkyl;
R8 is H, Hal, optionally substituted C1-6 alkyl, hydroxy, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 thioalkoxy,
wherein at least one of X1, X2, X4, and X5 is not CR8.
14. The compound of claim 13, wherein R2A has the formula:
each of X1 and X2 is independently selected from O, S, NH, N, or CH;
wherein at least one of X1 and X2 is not CH.
15. The compound of claim 11, wherein X1 is CH and X2 is S.
16. The compound of claim 14, wherein X1 is CH and X2 is S.
17. The compound of claim 1, wherein said compound has the formula of:
18. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient.
19. A method of treating or preventing a condition in a mammal caused by the action of nitric oxide synthase (NOS), wherein said method comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof to said mammal.
20. The method of claim 19, wherein said mammal is a human.
21. The method of claim 19, wherein said condition is migraine headache (with or without aura), chronic tension type headache (CTTH), migraine with allodynia, medication overuse headache, neuropathic pain, AIDS associated painful neuropathy, chronic headache, central post-stroke pain (CPSP), medication-induced hyperalgesia or allodynia, acute pain, chronic pain, diabetic neuropathy, trigeminal neuralgia, chemotherapy induced neuropathic pain, bone cancer pain, chemical dependencies or addictions, CNS disorders, neurodegenerative diseases or nerve injury, cardiovascular related conditions, diabetic nephropathy, inflammatory diseases, or gastrointestinal disorders.
22. The method of claim 21, wherein said medication-induced hyperalgesia or allodynia is opioid-induced hyperalgesiaallodynia or triptan (5-HT1D1B agonists)-induced hyperalgesia or allodynia.
23. The method of claim 21, wherein said chemotherapy induced neuropathic pain is induced by Paclitaxol, cis-Platin, or Doxorubicin.
24. The method of claim 21, wherein said chemical dependency or addiction is drug addiction, cocaine addiction, nicotine addiction, methamphetamine-induced neurotoxicity, ethanol tolerance, dependence, or withdrawal, or morphineopioid induced tolerance, dependence, hyperalgesia, or withdrawal.
25. The method of claim 21, wherein said CNS disorder is epilepsy, anxiety, depression, attention deficit hyperactivity disorder (ADHD), psychosis, or dementia.
26. The method of claim 21, wherein said neurodegenerative disease or nerve injury is acute spinal cord injury, AIDS associated dementia, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, multiple sclerosis, neurotoxicity, or head trauma.
27. The method of claim 21, wherein said cardiovascular related condition is stroke, coronary artery bypass graft (CABG) associated neurological damage, hypothermic cardiac arrest (HCA), post-stroke pain, cardiogenic shock, reperfusion injury, or vascular dementia.
28. The method of claim 21, wherein said inflammatory disease is osteoarthritis or neuroinflammation.
29. The method of claim 21, wherein said gastrointestinal disorder is ileostomy-associated diarrhea, dumping syndrome, or visceral pain.
30. The method of claim 21, wherein said condition is stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, chronic tension type headache, neuropathic pain, central post-stroke pain (CPSP), morphineopioid induced hyperalgesia or chronic pain.
31. The method of claim 19, wherein said condition is central post-stroke pain (CPSP).
32. The method of claim 19, wherein said method further comprises administering to said mammal an opioid.
33. The method of claim 32, wherein said opioid is alfentanil, butorphanol, buprenorphine, dextromoramide, dezocine, dextropropoxyphene, codeine, dihydrocodeine, diphenoxylate, etorphine, fentanyl, hydrocodone, hydromorphone, ketobemidone, loperamide, levorphanol, levomethadone, meperidine, meptazinol, methadone, morphine, morphine-6-glucuronide, nalbuphine, naloxone, oxycodone, oxymorphone, pentazocine, pethidine, piritramide, propoxyphene, remifentanil, sulfentanyl, tilidine, and tramadol.
34. The method of claim 19, wherein said method further comprises administering to said mammal an antidepressant.
35. The method of claim 34, wherein said antidepressant is a selective serotonin re-uptake inhibitor.
36. The method of claim 35, wherein said selective serotonin re-uptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline.
37. The method of claim 34, wherein said antidepressant is a norepinephrine-reuptake inhibitor.
38. The method of claim 37, wherein said norepinephrine-reuptake inhibitor is amitriptyline, desmethylamitriptyline, clomipramine, doxepin, imipramine, imipramine oxide, trimipramine; adinazolam, amiltriptylinoxide, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, amineptine, butriptyline, demexiptiline, dibenzepin, dimetacrine, dothiepin, fluacizine, iprindole, lofepramine, melitracen, metapramine, norclolipramine, noxiptilin, opipramol, perlapine, pizotyline, propizepine, quinupramine, reboxetine, or tianeptine.
39. The method of claim 34, wherein said antidepressant is a selective noradrenalinenorepinephrine reuptake inhibitor.
40. The method of claim 39, wherein selective noradrenalinenorepinephrine reuptake inhibitor is atomoxetine, bupropion, reboxetine, or tomoxetine.
41. The method of claim 34, wherein said antidepressant is a dual serotoninnorepinephrine reuptake inhibitor.
42. The method of claim 41, wherein said dual serotoninnorepinephrine reuptake inhibitor is duloxetine, milnacipran, mirtazapine, nefazodone, or venlafaxine.
43. The method of claim 34, wherein said antidepressant is a monoamine oxidase inhibitor.
44. The method of claim 43, wherein said monoamine oxidase inhibitor is amiflamine, iproniazid, isocarboxazid, M-3-PPC (Draxis), moclobemide, pargyline, phenelzine, tranylcypromine, or vanoxerine.
45. The method of claim 34, wherein said antidepressant is a reversible monoamine oxidase type A inhibitor.
46. The method of claim 45, wherein said reversible monoamine oxidase type A inhibitor is bazinaprine, befloxatone, brofaromine, cimoxatone, or clorgyline.
47. The method of claim 34, wherein said antidepressant is a tricyclic.
48. The method of claim 47, wherein said tricyclic is amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, or trimipramine.
49. The method of claim 34, wherein said antidepressant is adinazolam, alaproclate, amineptine, amitriptylinechlordiazepoxi-de combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, lithium, litoxetine; lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, trazodone, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viloxazine, viqualine, zimelidine, or orzometrapine.
50. The method of claim 19, wherein said method further comprises administering to said mammal an antiepileptic.
51. The method of claim 50, wherein said antiepileptic is carbamazepine, flupirtine, gabapentin, lamotrigine, oxcarbazepine, phenyloin, retigabine, topiramate, or valproate.
52. The method of claim 19, wherein said method further comprises administering to said mammal a non-steroidal anti-inflammatory drug (NSAID) or acetaminophen.
53. The method of claim 52, wherein said NSAID is acemetacin, aspirin, celecoxib, deracoxib, diclofenac, diflunisal, ethenzamide, etofenamate, etoricoxib, fenoprofen, flufenamic acid, flurbiprofen, lonazolac, lornoxicam, ibuprofen, indomethacin, isoxicam, kebuzone, ketoprofen, ketorolac, naproxen, nabumetone, niflumic acid, sulindac, tolmetin, piroxicam, meclofenamic acid, mefenamic acid, meloxicam, metamizol, mofebutazone, oxyphenbutazone, parecoxib, phenidine, phenylbutazone, piroxicam, propacetamol, propyphenazone, rofecoxib, salicylamide, suprofen, tiaprofenic acid, tenoxicam, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-2-(cyclohexyloxy)-4-nitrophenylmethanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-4-(methylsulfonyl)phenyl-3(2H)-pyridazinone, and 2-(3,5-difluorophenyl)-3-4-(methylsulfonyl)phenyl-2-cyclopenten-1-one).
54. The method of claim 19, wherein said method further comprises administering to said mammal an antiarrhythmic.
55. The method of claim 19, wherein said method further comprises administering to said mammal a GABA-B antagonist.
56. The method of claim 19, wherein said method further comprises administering to said mammal an alpha-2-adrenergic receptor agonist.
57. The method of claim 19, wherein said method further comprises administering to said mammal a serotonin 5HT1B1D agonist.
58. The method of claim 57, wherein said serotonin 5HT1B1D agonist is eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, donitriptan, or zolmitriptan.
59. The method of claim 19, wherein said method further comprises administering to said mammal an N-methyl-D-aspartate antagonist or glutamate receptor antagonist.
60. The method of claim 59, wherein said N-methyl-D-aspartate antagonist or glutamate receptor antagonist is amantadine; aptiganel; besonprodil; budipine; conantokin G; delucemine; dexanabinol; dextromethorphan; dextropropoxyphen; felbamate; fluorofelbamate; gacyclidine; glycine; ipenoxazone; kaitocephalin; ketamine; ketobemidone; lanicemine; licostinel; midafotel; memantine; D-methadone; D-morphine; milnacipran; neramexane; orphenadrine; remacemide; sulfazocine; FPL-12,495 (racemide metabolite); topiramate; (\u03b1R)-\u03b1-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid; 1-aminocyclopentane-carboxylic acid; 5-(aminomethyl)-2-(5S)-9-chloro-2,3,6,7-tetrahydro-2,3-dioxo-1H,5H-pyrido1,2,3-dequinoxalin-5-ylacetylaminophenoxy-acetic acid; \u03b1-amino-2-(2-phosphonoethyl)-cyclohexanepropanoic acid; \u03b1-amino-4-(phosphonomethyl)-benzeneacetic acid; (3E)-2-amino-4-(phosphonomethyl)-3-heptenoic acid; 3-(1E)-2-carboxy-2-phenylethenyl-4,6-dichloro-1H-indole-2-carboxylic acid; 8-chloro-2,3-dihydropyridazino4,5-bquinoline-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium; N\u2032-2-chloro-5-(methylthio)phenyl-N-methyl-N-3-(methylthio)phenyl-guanidine; N\u2032-2-chloro-5-(methylthio)phenyl-N-methyl-N-3-(R)-methylsulfinylphenyl-guanidine; 6-chloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H-indeno1,2-bpyrazine-9-acetic acid; 7-chlorothiokynurenic acid; (3S,4aR,6S,8aR)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; (\u2212)-6,7-dichloro-1,4-dihydro-5-3-(methoxymethyl)-5-(3-pyridinyl)-4-H-1,2,4-triazol-4-yl-2,3-quinoxalinedione; 4,6-dichloro-3-(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl-1H-indole-2-carboxylic acid; (2R,4S)-rel-5,7-dichloro-1,2,3,4-tetrahydro-4-(phenylamino)carbonylamino-2-quinolinecarboxylic acid; (3R,4S)-rel-3,4-dihydro-3-4-hydroxy-4-(phenylmethyl)-1-piperidinyl-2H-1-benzopyran-4,7-diol; 2-(2,3-dihydro-1H-inden-2-yl)amino-acetamide; 1,4-dihydro-6-methyl-5-(methylamino)methyl-7-nitro-2,3-quinoxalinedione; 2-(8,9-dioxo-2,6-diazabicyclo5.2.0non-1(7)-en-2-yl)ethyl-phosphonic acid; (2R,6S)-1,2,3,4,5,6-hexahydro-3-(2S)-2-methoxypropyl-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol; 2-hydroxy-5-(pentafluorophenyl)methylamino-benzoic acid; 1-2-(4-hydroxyphenoxy)ethyl-4-(4-methylphenyl)methyl-4-piperidinol; 1-4-(1H-imidazol-4-yl)-3-butynyl-4-(phenylmethyl)-piperidine; 2-methyl-6-(phenylethynyl)-pyridine; 3-(phosphonomethyl)-L-phenylalanine; or 3,6,7-tetrahydro-2,3-dioxo-N-phenyl-1H,5H-pyrido1,2,3-dequinoxaline-5-acetamide.
61. The method of claim 19, wherein said method further comprises administering to said mammal a cholecystokinin B antagonist.
62. The method of claim 19, wherein said method further comprises administering to said mammal a substance P antagonist.
63. The method of claim 19, wherein said method further comprises administering to said mammal an anti-inflammatory compound.
64. The method of claim 63, wherein said anti-inflammatory compound is aspirin, celecoxib, cortisone, deracoxib, diflunisal, etoricoxib, fenoprofen, ibuprofen, ketoprofen, naproxen, prednisolone, sulindac, tolmetin, piroxicam, mefenamic acid, meloxicam, phenylbutazone, rofecoxib, suprofen, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-2-(cyclohexyloxy)-4-nitrophenylmethanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-4-(methylsulfonyl)phenyl-3(2H)-pyridazinone, or 2-(3,5-difluorophenyl)-3-4-(methylsulfonyl)phenyl-2-cyclopenten-1-one.
65. The method of claim 19, wherein said method further comprises administering to said mammal a DHP-sensitive L-type calcium channel antagonist, omega-conotoxin-sensitive N-type calcium channel antagonist, or a PQ-type calcium channel antagonist.
66. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine kinase antagonist.
67. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine receptor A1 agonist, an adenosine receptor A2a antagonist or an adenosine receptor A3 agonist.
68. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine deaminase inhibitor.
69. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine nucleoside transport inhibitor.
70. The method of claim 19, wherein said method further comprises administering to said mammal a vanilloid VR1 receptor agonist.
71. The method of claim 19, wherein said method further comprises administering to said mammal a cannabinoid CB1CB2 agonist.
72. The method of claim 19, wherein said method further comprises administering to said mammal an AMPA receptor antagonist.
73. The method of claim 19, wherein said method further comprises administering to said mammal a kainate receptor antagonist.
74. The method of claim 19, wherein said method further comprises administering to said mammal a sodium channel blocker.
75. The method of claim 19, wherein said method further comprises administering to said mammal a nicotinic acetylcholine receptor agonist.
76. The method of claim 19, wherein said method further comprises administering to said mammal a KATP potassium channel, Kv1.4 potassium channel, Ca2+-activated potassium channel, SK potassium channel, BK potassium channel, IK potassium channel, or KCNQ23 potassium channel opening agent.
77. The method of claim 19, wherein said method further comprises administering to said mammal a muscarinic M3 antagonist, a muscarinic M1 agonist, or a muscarinic M2M3 partial agonistantagonist.
78. The method of claim 19, wherein said method further comprises administering to said mammal an antioxidant.
79. The method of claim 19, wherein said method further comprises administering to said mammal an antipsychotic agent.
80. The method of claim 79, wherein said antipsychotic agent is promazine, chlorpromazine, chlorprothixene, thioridazine, acetophenazine, mesoridazine, droperidol, loxapine, molindone, perphenazine, prochlorphenazine, thiothixene, trifluoperazine, fluphenazine, pimozide, flupenthixol, methotrimeprazine, pipotiazine, sertindole, clozapine, olanzapine, risperidone, aripiprazole, quetiapine, haloperidol, ziprasidone, or iloperidone.
81. The method of claim 19, wherein said method further comprises administering to said mammal a dopamine receptor antiparkinson’s agent
82. The method of claim 81, wherein said antiparkinson’s agent is levodopa, or pramipexole.
83. The method of claim 19, wherein said method further comprises administering to said mammal Fatty Acid Amide Hydrolase (FAAH) Inhibitor.